Literature DB >> 9570407

Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium.

K Mdluli1, J Swanson, E Fischer, R E Lee, C E Barry.   

Abstract

Isoniazid (INH), which acts by inhibiting mycolic acid biosynthesis, is very potent against the tuberculous mycobacteria. It is about 100-fold less effective against Mycobacterium avium. This difference has often been attributed to a decreased permeability of the cell wall. We measured the rate of conversion of radiolabelled INH to 4-pyridylmethanol by whole cells and cell-free extracts and estimated the permeability barrier imposed by the cell wall to INH influx in Mycobacterium tuberculosis and M. avium. There was no significant difference in the relative permeability to INH between these two species. However, the total conversion rate in M. tuberculosis was found to be four times greater. Examination of in vitro-generated mutants revealed that the major resistance mechanism for both species is loss of the catalase-peroxidase KatG. Analysis of lipid and protein biosynthetic profiles demonstrated that the molecular target of activated INH was identical for both species. M. avium, however, formed colonies at INH concentrations inhibitory for mycolic acid biosynthesis. These mycolate-deficient M. avium exhibited altered colony morphologies, modified cell wall ultrastructure and were 10-fold more sensitive to treatment with hydrophobic antibiotics, such as rifampin. These findings may significantly impact the design of new therapeutic regimens for the treatment of infections with atypical mycobacteria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570407     DOI: 10.1046/j.1365-2958.1998.00774.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  21 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

Review 2.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

3.  The two-component regulatory system mtrAB is required for morphotypic multidrug resistance in Mycobacterium avium.

Authors:  Gerard A Cangelosi; Julie S Do; Robert Freeman; John G Bennett; Makeda Semret; Marcel A Behr
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine.

Authors:  N B Harris; R G Barletta
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

5.  Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro.

Authors:  C Manca; S Paul; C E Barry; V H Freedman; G Kaplan
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  Exponential-phase glycogen recycling is essential for growth of Mycobacterium smegmatis.

Authors:  A E Belanger; G F Hatfull
Journal:  J Bacteriol       Date:  1999-11       Impact factor: 3.490

7.  A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates.

Authors:  J Liu; H Nikaido
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  Unveiling unusual features of formation of septal partition and constriction in mycobacteria--an ultrastructural study.

Authors:  Srinivasan Vijay; Deepak Anand; Parthasarathi Ajitkumar
Journal:  J Bacteriol       Date:  2011-11-18       Impact factor: 3.490

9.  Genes required for intrinsic multidrug resistance in Mycobacterium avium.

Authors:  Julie S Philalay; Christine O Palermo; Kirsten A Hauge; Tige R Rustad; Gerard A Cangelosi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.